Increased Plasma Propranolol Binding in Myocardial Infarction

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1980 Apr 1

PMID 7378264

Citations 6

Authors

P A Routledge

W W Stargel

G S Wagner

D G SHAND

Affiliations

Soon will be listed here.

Citing Articles

beta-blocker plasma concentrations and inflammatory disease: clinical implications.

Schneider R, Bishop H Clin Pharmacokinet. 1982; 7(4):281-4.

PMID: 7116736 DOI: 10.2165/00003088-198207040-00001.

Therapeutic drug monitoring of antiarrhythmic agents.

Brown J, SHAND D Clin Pharmacokinet. 1982; 7(2):125-48.

PMID: 7039925 DOI: 10.2165/00003088-198207020-00003.

Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness.

Paxton J, Briant R Br J Clin Pharmacol. 1984; 18(5):806-10.

PMID: 6508990 PMC: 1463558. DOI: 10.1111/j.1365-2125.1984.tb02548.x.

The plasma protein binding of basic drugs.

Routledge P Br J Clin Pharmacol. 1986; 22(5):499-506.

PMID: 3790398 PMC: 1401182. DOI: 10.1111/j.1365-2125.1986.tb02927.x.

Free drug concentration monitoring in clinical practice. Rationale and current status.

Svensson C, Woodruff M, BAXTER J, Lalka D Clin Pharmacokinet. 1986; 11(6):450-69.

PMID: 3542337 DOI: 10.2165/00003088-198611060-00003.

References

Balcon R, Jewitt D, Davies J, Oram S . A controlled trial of propranolol in acute myocardial infarction. Lancet. 1966; 2(7470):918-20. View

Clausen J, Felsby M, Jorgensen F, Nielsen B, Roin J, Strange B . Absence of prophylactic effect of propranolol in myocardial infarction. Lancet. 1966; 2(7470):920-4. DOI: 10.1016/s0140-6736(66)90533-2. View

Norris R, Caughey D, Scott P . Trial of propranolol in acute myocardial infarction. Br Med J. 1968; 2(5602):398-400. PMC: 1985983. DOI: 10.1136/bmj.2.5602.398. View

BACHMANN G, Weiss M, Rapp W . [Differentiated quantitative serum protein determination during myocardial infarct]. Schweiz Med Wochenschr. 1968; 98(46):1825-9. View

Coltart D, SHAND D . Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man. Br Med J. 1970; 3(5725):731-4. PMC: 1701661. DOI: 10.1136/bmj.3.5725.731. View

Johansson B, Kindmark C, Trell E, Wollheim F . Sequential changes of plasma proteins after myocardial infarction. Scand J Clin Lab Invest Suppl. 1972; 124:117-26. DOI: 10.3109/00365517209102759. View

McDevitt D, Frisk-Holmberg M, Hollifield J, SHAND D . Plasma binding and the affinity of propranolol for a beta receptor in man. Clin Pharmacol Ther. 1976; 20(2):152-7. DOI: 10.1002/cpt1976202152. View

Peter T, Norris R, Clarke E, Heng M, Singh B, Williams B . Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation. 1978; 57(6):1091-5. DOI: 10.1161/01.cir.57.6.1091. View

Norris R, Clarke E, Sammel N, Smith W, Williams B . Protective effect of propranolol in threatened myocardial infarction. Lancet. 1978; 2(8096):907-9. DOI: 10.1016/s0140-6736(78)91628-8. View

10.

Piafsky K, Borga O, Odar-Cederlof I, Johansson C, Sjoqvist F . Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med. 1978; 299(26):1435-9. DOI: 10.1056/NEJM197812282992604. View

11.

Wood M, SHAND D, Wood A . Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling. Clin Pharmacol Ther. 1979; 25(1):103-7. DOI: 10.1002/cpt1979251103. View

12.

Sager G, Nilsen O, Jacobsen S . Variable binding of propranolol in human serum. Biochem Pharmacol. 1979; 28(6):905-11. DOI: 10.1016/0006-2952(79)90374-5. View

13.

Routledge P, SHAND D . Clinical pharmacokinetics of propranolol. Clin Pharmacokinet. 1979; 4(2):73-90. DOI: 10.2165/00003088-197904020-00001. View